STRATA Skin Sciences. has been granted a patent for a device that applies targeted phototherapy to treat diseased skin. The device includes a dosimetry component to determine the optimal UVB light dosage, facilitating effective treatment while minimizing skin damage. The design features an optical matrix for varied light transmission. GlobalData’s report on STRATA Skin Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on STRATA Skin Sciences, Radiotherapy techniques was a key innovation area identified from patents. STRATA Skin Sciences's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Targeted phototherapy device for treating diseased skin conditions
The patent US12005266B2 describes a dosimetry device designed to connect with a phototherapy apparatus for the targeted application of UVB light to diseased tissue. The device features a tubular housing that defines a single cavity, devoid of an internal light source, and is configured to connect directly to the phototherapy apparatus. At the distal end of the housing, a single optical matrix is incorporated, consisting of multiple transmissive regions that allow varying intensities of UVB light to pass through. These regions can include materials such as fused silica or UV-transmitting plastics, which may be coated with metallic or multi-dielectric materials to modulate light intensity. The device aims to determine the minimal blistering dose of UVB light necessary for effective treatment.
Additionally, the patent outlines a method for determining the maximum tolerable dose of phototherapy. This involves connecting the dosimetry device to the phototherapy apparatus, positioning it near the treatment area, and transmitting UVB light through the housing. The method includes using a jig with multiple openings to expose the diseased tissue to different radiation levels, allowing for the assessment of optimal dosage. The varying percentages of UVB light transmitted can range significantly, from 0% to 100%, depending on the specific region. Following treatment, the area is analyzed for blister formation to establish the minimum blistering dose, which informs the application of a maximum tolerable dose for therapeutic purposes. This systematic approach aims to optimize treatment while minimizing adverse effects.
To know more about GlobalData’s detailed insights on STRATA Skin Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
